InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints RNAi Pioneer Phillip Zamore to Scientific Advisory Board
May 28, 2025
TransCode Therapeutics (NASDAQ: RNAZ), has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, to its Scientific Advisory Board. Dr. Zamore, currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is renowned for his foundational work in RNA biology and gene silencing mechanisms. […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances RNA Cancer Therapy as 15 Patients Dosed in Phase 1a Trial
May 8, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced that the third patient in Cohort 4 of its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138 has been dosed, with 15 patients now treated across four dose levels. The Safety Review Committee approved expanded enrollment and noted no significant toxicities or disease progression to date. Ten patients remain on […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Sets 1-for-28 Reverse Stock Split Effective May 15
May 6, 2025
TransCode Therapeutics (NASDAQ: RNAZ), the RNA oncology company focused on developing RNA therapeutics to treat cancer, will implement a 1-for-28 reverse stock split effective May 15, 2025, at 12:01 a.m. EDT. Shares will begin trading on a split-adjusted basis that same day under the existing ticker, “RNAZ.” The move, approved by shareholders and the board, […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
May 1, 2025
TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD […]
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Adjourns Special Meeting Due to Lack of Quorum
April 22, 2025
TransCode Therapeutics (NASDAQ: RNAZ) announced that its April 21 special meeting has been adjourned to May 2 at 9:30 a.m. Eastern after failing to meet the quorum requirement. Only 12.73% of eligible shares were represented, below the one-third threshold. The adjournment is intended to allow further proxy solicitation on two proposals: a reverse stock split […]
InvestorNewsBreaks – TransCode Therapeutics Inc. (NASDAQ: RNAZ) Secures $10M in Registered Direct Offering
March 27, 2025
TransCode (NASDAQ: RNAZ), the oncology company committed to utilizing RNA therapeutics to more effectively treat cancer, has announced the closing of its sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and […]
ROTH MKM to Host 9th Annual London Conference on June 20-22, 2023
June 13, 2023
NEWPORT BEACH, Calif., June 13, 2023 (GLOBE NEWSWIRE) — via IBN — ROTH MKM (“Roth”), www.roth.com, will host the 9th Annual Roth London Conference on June 20-22, 2023, at Four Seasons Hotel London at Park Lane in London, UK. This event will provide institutional investors the unique opportunity to meet with C-suite leaders and executive management teams from approximately 70 […]
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
November 15, 2021
Virtual: November 16 – 17, 2021 Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 presenting companies from a wide spectrum […]